Arcus Biosciences stock trades at 17.69 US dollars after-hours
Published on 11/06/2026 at 01:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat investors should watch
- Arcus is developing a pipeline of cancer and immune-disease therapies.
- Casdatifan is the company’s lead program for kidney cancer.
- The company remains a clinical-stage biotechnology specialist based in California.
Arcus Biosciences stock traded at 17.69 US dollars on the New York Stock Exchange at 10:00 p.m. CET on Thursday, Nov. 5. The after-hours quote provides the latest market reference for investors ahead of the next regular session.
Pipeline remains central
Arcus is developing cancer and immune-disease therapies, with casdatifan as its lead program in kidney cancer. Its broader pipeline includes domvanalimab, zimberelimab, quemliclustat, AB598 and AB801 across clinical programs targeting lung, gastrointestinal, pancreatic and other cancers.
Clinical-stage biotech profile
Arcus Biosciences is based in Hayward, California, and operates as a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapies in the United States. The company also collaborates with AstraZeneca on clinical development programs, including studies involving domvanalimab and casdatifan.
Arcus Biosciences at a glance
- Company: Arcus Biosciences, Inc.
- Ticker: RCUS
- Latest quote: 17.69 US dollars
- Quote time: Thursday, Nov. 5, 2026, 10:00 p.m. CET
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters: Hayward, California, United States
